GLP-1s: Policy And Access Trends In A Rapidly Evolving Landscape Health Affairs

https://www.linkedin.com/pulse/glp-1s-policy-access-trends-rapidly-evolving-landscape-mrsje/ Both public and private payers have placed tight restrictions on coverage of GLP-1s for the treatment of obesity, and out-of-pocket prices can be too steep for many populations. The policy landscape is shifting extremely quickly, however, as consumer demand grows and policy makers begin to reassess the calculus of health care spending on obesity-related conditions. Exclusive to Health Affairs Insiders, this new report examines why coverage and access to GLP-1 medications are uneven as of early 2026, and explores emerging trends in coverage, affordability, and access. KEY POINTS Obesity affects four in ten US adults and costs more than $261 billion per year. As a drug class, GLP-1s have been FDA approved for a number of different clinical indications other than obesity, which complicates coverage. Most payers will cover GLP-1s to treat type 2 diabetes and are increasing coverage for other FDA-approved indications such as cardiovascular health and sleep apnea, all of which are clinically intertwined with obesity. The current interpretation of Medicare Part D statute prevents coverage of drugs when used for weight loss, including GLP-1s, but does not prohibit GLP-1 coverage for other FDA-approved indications. The GLP-1 marketplace is dynamic and highly competitive, with overlapping tensions informing the competition between manufacturers and distributors about how patients access these therapies. https://www.healthaffairs.org/content/briefs/glp-1s-policy-and-access-trends-rapidly-evolving-landscape?utm_medium=email&utm_source=linkedin+newsletter&utm_campaign=insidermarketing&utm_content=reportspecific